GEO Investing

By: Jay Thompson of SkyTides Inc., with significant support from various experts.

The Spectranetics Corporation (NMS:SPNC), a medical devices manufacturer, is up 150%+ and about $750M in market capitalization on hype of its new product, Stellarex.

Before getting into Stellarex itself, we want to point out that SPNC management are currently accused of various securities frauds.  Furthermore, they appear to routinely overhype the prospects of their “new” products. AngioScore and the ISR indication for SPNC’s disposable lasers (“ISR”) are two clear examples of hype that was not only unfounded to begin with but was also aggressively pushed on investors when management was allegedly fully aware their words were untrue. During 2014 and 2015, management suggested AngioScore would not be impacted by the launch of drug-coated balloon (“DCBs”). After almost a year of strong denials, management finally admitted DCBs were stunting AngioScore’s growth. The management team followed the same game plan with ISR when the FDA approved it in July 2014. Management hyped this FDA approval, suggesting to investors that ISR would boost SPNC’s sales. Yet, they allegedly knew physicians were already using ISR “off-label.” Off-label use of the lasers was already generating revenue for SPNC and its sales personnel did not see further growth ahead so the FDA approval was essentially a non-event. These facts appear as though they were well-known internally at SPNC but investors were told a different narrative. As expected in any fraudulent scheme, the AngioScore and ISR hype eventually succumbed to reality in 2015 and SPNC’s stock price dropped 66% in response.

Today’s report covers the following:


1. SPNC has serious disclosure related issues including

  • SPNC did not disclose 12 recent patient death allegations by medical professionals “against” SPNC devices
  • FDA alleges SPNC deliberately withheld adverse event reports from the FDA
  • Unacceptable surgeon injuries – SPNC laser device emits accidental radiation and causes “burns to the gown, glove and finger of physician”

2. PNC did not disclose the largest recall in SPNC history in November 2016

3. Stellarex pivotal clinical data is “worst-in-class” for both primary efficacy and primary safety measures

4. Further analysis of primary efficacy measure shows competitors’ clinical data outclassing Stellarex by a factor of 16X and 9X, Stellarex really is “worst-in-class”

5. SPNC data-mined non-performance related demographic “differentiators” and successfully sold a flawed narrative to the street, our experts claim differentiators are trivial and highly unlikely to impress the FDA or cause hospitals to choose Stellarex

6. Medtronic, the DCB market leader, recently dropped its estimate of the worldwide DCB market by 23%, while SPNC’s industry forecasts became even more aggressive

7. Stellarex sales have failed in Europe, the only market it is approved in, supporting our view that projections of U.S. sales, if Stellarex is approved, are wildly inflated

8. A closer look at clinical data suggests “fortuitous flattening” or “manufactured data” was the difference between success and failure of the Stellarex Pivotal Trial

9. SPNC discloses its promotion of the AngioScore product included assumptions that were “materially inaccurate” and that these material inaccuracies may occur again — specifically mentioning Stellarex

10. Recent commentary by sell-side analysts highlights “” and “flat to down performance”

11. SPNC likely requires $100M+ in new capital but is already highly levered with over $300M in debt – a dilutive equity raise would crush the stock; daily liquidity is just $9M

12. Short term price target: $8 (70% downside)

Our research included interviews and in-depth analysis of various issues included in this report by 6 experts in fields relevant to the content in this report. We advise all readers of this report to read the biographies provided in Exhibit 5 to this report.

Please see SkyTides entire report here.

SkyTides Disclaimer(s):


We are short shares of SPNC and are long SPNC puts. We may add to our short position at any time. All information included within this report is sourced from publicly available materials. As of the publication of this report we have not communicated with the executive management of SPNC or their shareholders.

By viewing material on this website you agree to the following Terms of Service. You agree that use of SkyTides Inc.’s (“SkyTides”) research is at your own risk. In no event will you hold SkyTides or any affiliated party liable for any direct or indirect trading losses caused by any information on this site. You further agree to do your own research and due diligence before making any investment decision with respect to securities covered herein. You represent to SkyTides that you have sufficient investment sophistication to critically assess the information, analysis and opinion on this site. You further agree that you will not communicate the contents of this report to any other person unless that person has agreed to be bound by these same terms of service. If you download or receive the contents of this report as an agent for any other person, you are binding your principal to these same Terms of Service. Unless otherwise stated within an “additional disclaimer” with this article, you should assume that as of the publication date of our reports and research, SkyTides (possibly along with or through our members, partners, affiliates, employees, and/or consultants) along with our subscribers, clients and/or investors and/or their clients and/or investors has a long or short position in all stocks (and/or options, swaps, and other derivatives related to the stock) and bonds covered herein, and therefore stands to realize significant gains in the event that the price of either increases or declines. Our employees, partners, members, affiliates, family members and others may also transact in the shares of the stock we discuss in our research. Certain individuals and entities have paid or may pay us in the future for access to our research prior to it being made publicly available.  We intend to continue transacting in the securities of issuers covered on this site for an indefinite period after our first research article or research note, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation.  This is not an offer to sell or a solicitation of an offer to buy any security, nor shall SkyTides offer, sell or buy any security to or from any person through the SkyTides website at SkyTides is not registered as an investment advisor in any jurisdiction.  You acknowledge that the author(s) of any publication released by SkyTides at,, or do not hold any accreditation such as the Chartered Financial Analyst designation, or other comparable designations, to perform any valuation services related to any investment opportunity discussed by SkyTides.  If you are in the United Kingdom, you confirm that you are accessing research and materials as or on behalf of: (a) an investment professional falling within Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “FPO”); or (b) high net worth entity falling within Article 49 of the FPO.  Our research and reports express our opinions, which we have based upon generally available information, field research, communications with management (only when specifically indicated), inferences and deductions through our due diligence and analytical process. To the best of our ability and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and who are not insiders or connected persons of the stock covered herein or who may otherwise owe any fiduciary duty or duty of confidentiality to the issuer, unless otherwise specifically indicated.  However, such information is presented “as is,” without warranty of any kind, whether express or implied. SkyTides makes no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information or with regard to the results to be obtained from its use. Further, any report on this site contains a very large measure of analysis and opinion. All expressions of opinion are subject to change without notice, and SkyTides does not undertake to update or supplement any research articles or research notes or any of the information, analysis and opinion contained in them. You agree that the information on this website is copyrighted, and you therefore agree not to distribute this information (whether the downloaded file, copies / images / reproductions, or the link to these files) in any manner other than by providing the following link: If you have obtained SkyTides research articles or research notes in any manner other than by viewing from the SkyTides website at, you may not read such research without going to and reading the Terms of Service. You further agree that any dispute arising from your use of this report and / or the SkyTides website or viewing the material hereon shall be governed by the laws of the British Virgin Islands (“BVI”), without regard to any conflict of law provisions. You knowingly and independently agree to submit to the personal and exclusive jurisdiction of the courts located within the BVI and waive your right to any other jurisdiction or applicable law. The failure of SkyTides to exercise or enforce any right or provision of these Terms of Service shall not constitute a waiver of this right or provision. If any provision of these Terms of Service is found by a court of competent jurisdiction to be invalid, the parties nevertheless agree that the court should endeavor to give effect to the parties’ intentions as reflected in the provision and rule that the other provisions of these Terms of Service remain in full force and effect, in particular as to this governing law and jurisdiction provision. You agree that regardless of any statute or law to the contrary, any claim or cause of action arising out of or related to use of this website or the material herein must be filed within one (1) year after such claim or cause of action arose or be forever barred.

GeoInvesting Disclaimer(s):

Unless otherwise noted and/or explicitly disclosed, you should assume that as of the publication date of our and our contributor’s reports and research, GeoInvesting (possibly along with or through our members, partners, affiliates, employees, contributors, and/or consultants) along with our clients and/or investors and/or their clients and/or investors has an investment position in all stocks (and/or options, swaps, and other derivatives related to the stock) and bonds covered therein (either long or short depending on our investment opinion), and therefore stands to realize significant gains in the event that the price of changes in conjunction with our investment opinion. We intend to continue transacting in the securities of issuers covered on this site for an indefinite period after our first report, and we may be long, short, or neutral at any time hereafter regardless of our initial investment opinion.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.